Jersey City, N.J. – September 17, 2026 -- Tenon Medical, Inc. (NASDAQ: TNON) has closed a warrant inducement agreement generating $2,872,338.58 in gross proceeds from an institutional investor exercising 572,179 outstanding warrants in full.
Institutional investor exercises warrants for immediate cash proceeds
The exercising holder converted 572,179 existing warrants into common stock, delivering gross cash proceeds of $2,872,338.58 to Tenon before deducting advisor fees and other expenses.
Company issues new warrants covering 858,269 shares at $5.02 exercise price
In exchange for the immediate exercise, the investor received new unregistered warrants to purchase up to 858,269 shares of common stock, equal to 150% of the shares issued in the original exercise. The new warrants carry a $5.02 per-share exercise price, are immediately exercisable upon issuance, and expire five years from that date.
WallachBeth Capital served as financial advisor on the transaction
WallachBeth Capital LLC structured and advised on the warrant inducement deal for Tenon, a medical device company focused on treatments for sacro-pelvic disorders.
New warrants sold via private placement exemption, resale registration pending
The new warrants and underlying shares were issued under an exemption from registration requirements of the Securities Act of 1933 and have not been registered with the SEC. Tenon has committed to filing a resale registration statement covering the shares issuable upon exercise of the new warrants.